Search Results
Your search for early matches 10467 pages
Showing 8251 - 8300Disparities in Cancer Care: How A Deep South Community Overcame Them
Racial inequities were a daily observation for Edward E. Partridge, MD, growing up in Alabama during the civil rights era. When he became a physician, he saw that these disparities extended into his own field, gynecologic oncology. He decided to do something about it. Dr. Partridge recently...
Managing Female Reproductive Complications after Cancer Treatment in Children and Young Adults
Follow-up care for female patients treated for cancer as children, adolescents, or young adults should include assessment and management of the late effects that therapy may have on reproductive health, as detailed in updated guidelines from the Children’s Oncology Group. “It is important for...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma
FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...
Women in Oncology: Trending in the Right Direction
According to ASCO President Sandra M. Swain, MD, FACP, an important part of her Presidential theme, “Building Bridges to Conquer Cancer,” is finding creative ways to ensure that we have enough oncologists to care for our burgeoning cancer patient population. Adding more women to the oncology...
Breakthroughs in Targeted Therapies for Breast Cancer Are Improving Patient Survival Rates
For more than 20 years, José Baselga, MD, PhD, has devoted his medical and scientific career to caring for breast cancer patients and the development of novel molecular targeted agents to treat the disease. From 1996 to 2010, he was Head of the Oncology Department of Vall d’Hebron University...
Breast Cancer Survivors Not Likely to Maintain Physical Activity Sufficient for Benefits of Exercise
Few breast cancer survivors meet national exercise recommendations during the 10 years after being diagnosed, even though they are among the women who could most benefit from regular physical activity, according to a study by researchers at Fred Hutchinson Cancer Research Center. Prior studies and...
University of Michigan Launches New Cardio-oncology Program
The University of Michigan Samuel and Jean Frankel Cardiovascular Center, working with specialists at the University of Michigan (U-M) Comprehensive Cancer Center, has launched Michigan’s first cardio-oncology clinic, a program designed to prevent or minimize heart damage caused by chemotherapy and ...
Reducing Incidental Cardiac Irradiation during Breast Radiotherapy
In the treatment of breast cancer, a wealth of data from prospective clinical trials and meta-analyses has documented the benefits of radiation to prevent local-regional recurrence and improve survival. Accordingly, important quality indicators in breast cancer care include: (1) receipt of...
SIDEBAR: Left-sided Adjuvant Breast Radiotherapy: A Change of Heart?
Darby and colleagues are to be congratulated for an ambitious population-based case-control study that demonstrates the impact of postoperative adjuvant ionizing radiation for early-stage breast cancer on ischemic heart disease.1 The study examined roughly 1,000 cases and 1,000 controls in Sweden...
Greater Prediagnosis Soy Food Consumption Associated with Improved Survival in Women with Lung Cancer
As recently reported by Gong Yang, MD, MPH, Research Associate Professor at Vanderbilt University School of Medicine, Nashville, and colleagues in the Journal of Clinical Oncology,1 higher prediagnosis consumption of soy food was associated with improved overall survival in Chinese women with lung...
New Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitor Treatment
A new guideline for molecular testing to select lung cancer patients for treatment with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors has been jointly developed by the College of American Pathologists, International Association for the Study ...
Breakthrough Therapy Designation for Lambrolizumab for the Treatment of Advanced Melanoma
Merck has announced that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck’s investigational antibody therapy targeting the programmed death receptor (PD-1) that...
Ibrutinib Receives Third Breakthrough Therapy Designation from the FDA
Pharmacyclics, Inc, announced that the FDA has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma with deletion of the short arm of...
ASCO Announces New Conflict of Interest Policy
In April, ASCO released its updated conflict of interest policy in the development and presentation of scientific research and educational content. The revised policy is designed to increase transparency in financial relationships between individuals and health-care companies and impose new...
Interventional Radiologists Report Novel Approaches for Metastatic Lesions
For the treatment of metastases to the liver and the lung, interventional radiologists reported early success with two novel approaches at the Society of Interventional Radiology (SIR) 38th Annual Scientific Meeting, held recently in New Orleans. Cryoablation of Lung Tumors For patients with...
Early Data Promising for Concurrent Sorafenib Plus Embolization in Metastatic Liver Cancer
If sorafenib (Nexavar) and local ablation techniques are both effective in the treatment of metastatic hepatocellular carcinoma, could they deliver an even greater punch when combined? The concurrent use of interventional radiology approaches and sorafenib for metastatic hepatocellular carcinoma is ...
More Recollections on Emil 'Tom' Frei III, MD
I have read with interest the recent tributes to Emil “Tom” Frei III, MD, who passed away in April. I was backstage at the ASCO Annual Meeting in 1981, when Dr. Frei was giving his Karnofsky acceptance address. I had a slide presentation at the combined ASCO/American Association for Cancer Research ...
Older Patients and Those with Comorbidities Are Less Likely to Receive Palliative Radiotherapy
Older patients and those with comorbid conditions are less likely to receive palliative radiotherapy, according to an analysis of data from 51,610 patients with stage IV breast, prostate, lung, or colorectal cancer. The study also found that black patients with prostate cancer were 20% less likely...
Smoking Early in Life Is More Strongly Associated with Increased Risk of Breast Cancer
Analyses of data from 73,388 women in the American Cancer Society’s Cancer Prevention Study II (CPS-II) Nutrition Cohort and from a meta-analysis including 14 other studies “support the hypothesis that active smoking increases the risk of breast cancer, especially when smoking begins at an early...
Surgery Delays Longer Than 6 Weeks in Young Women with Breast Cancer Decrease Survival
Delays of more than 6 weeks from time of diagnosis until surgical treatment of breast cancer among young women significantly decreases survival times compared to those with a shorter treatment delay time, according to a study in JAMA Surgery. “This adverse impact on survival was more pronounced in...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need chemotherapy,” investigators ...
Innovative State Program Reduces Colorectal Cancer Disparities, Mortality Rates Among African American Patients
A study analyzing the impact of the Delaware Cancer Consortium, the state’s cancer control program, reports a 41% reduction in colorectal mortality rates for African Americans.1 The recently published study provided analysis on a novel design and approach used to eliminate colorectal cancer...
Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...
American Cancer Society Marks 100th Year Anniversary
The American Cancer Society announced the Society’s 100th birthday on May 22, 2013. Founded 100 years ago by 15 prominent physicians and business leaders in New York, the American Cancer Society, first known as the American Society for the Control of Cancer, launched the fight against a disease...
Making Prevention and Early Detection of Cancer a Priority
Conquering cancer has been the goal of Bert Vogelstein, MD, since he was a teenager in Baltimore. For more than 3 decades, Dr. Vogelstein, Co-Director of the Ludwig Center for Cancer Genetics and Therapeutics and Investigator of the Howard Hughes Medical Institute at Johns Hopkins Medical...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appeared online recently in the journal Cancer Research.1 Gleason...
Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer
According to an analysis reported by Amanda Phipps, PhD, MPH, Assistant Professor of Epidemiology at the University of Washington and Assistant Member at Fred Hutchinson Cancer Research Center, Seattle, and colleagues in the Journal of Clinical Oncology, patients with stage III colon cancer who...
EGFR Prevents Maturation of microRNAs under Hypoxic Conditions
The epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs under conditions of hypoxia, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The results were reported in an early online...
Genetic Diversity May Predict Outcomes in Head and Neck Cancer
A new measure of cell heterogeneity within a tumor may predict treatment outcomes of patients with squamous cell carcinoma of the head and neck. In a recent report,1 investigators at Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary reported how the mutant allele tumor...
HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
Liver transplantation for hepatocellular carcinoma is feasible for HIV-infected patients, with no differences in post-transplant survival or hepatocellular carcinoma recurrence rates compared with liver transplantation for hepatocellular carcinoma in HIV-uninfected patients. The study, published in ...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Results of the first of three planned annual screening examinations from the National Lung Screening Trial (NLST) were recently published and physicians may now have more information to share with their patients about the benefits and risks of low-dose computed tomography lung cancer screening.1...
ASCO Publishes New Conflict of Interest Policy
ASCO has released its new conflict of interest policy, ASCO Policy for Relationships With Companies, which updates its earlier policy in key ways that are designed to increase transparency in relationships with commercial interests. Comprehensive Framework The new policy establishes a more...
Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
The Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group recently announced that it has appointed Joseph A. Sparano, MD, as its Vice Chair. In his new role, Dr. Sparano will assist the Group leadership in defining research...
Determining the Best Diet for Patients with Cancer
How much does diet and body weight influence the effectiveness of cancer treatment and reduce the risk of cancer recurrence? What is the optimal diet for patients with cancer and survivors to follow? There are currently no hard and fast rules, but some dietary clues are starting to emerge. Search...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood.1 Acute...
Expert Point of View: Alison Freifeld, MD
The EORTC Infectious Diseases Group Trial XV “is a long-awaited study because it finally is an investigation of outpatient management of low-risk fever and neutropenia in a large number of patients,” Alison Freifeld, MD, of the University of Nebraska Medical Center in Omaha, commented in an...
Once-daily Moxifloxacin for Low-risk Patients with Febrile Neutropenia
Once-daily oral moxifloxacin works at least as well as twice-daily oral ciprofloxacin plus amoxicillin–clavulanic acid when it comes to treating febrile neutropenia in patients who are at low risk for complications, according to a randomized, double-blind trial reported in the Journal of Clinical...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
In a separate interview, Andrew D. Zelenetz, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, said that he found the relapse rate of 20% observed in this study to be quite low, and he wanted to know the characteristics of the 537 patients included in the ...
Expert Point of View: Sandra M. Swain, MD, FACP
Sandra M. Swain, MD, FACP, Immediate Past President of ASCO commented on the findings. “This is an exciting discovery and an example of early success in precision medicine. It’s targeting PI3K-delta, which is overactive in B-cell malignancies and is used in a disease that is very refractory to...
Potent Activity Shown for First-in-class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia
Heavily pretreated patients with chronic lymphocytic leukemia (CLL) responded robustly to the first-in-class small-molecule inhibitor idelalisib (formerly GS1101), in a phase I dose-finding study reported in a press briefing prior to the 2013 ASCO Annual Meeting.1 Idelalisib, a specific inhibitor...
Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies
Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...
Caring for the Whole Patient Both during Active Treatment and at End of Life
Despite studies showing that a majority of patients prefer to die at home rather than in an institutional setting,1 in many parts of the country, over 30% die in nursing homes and over 50% die in hospitals, according to Ira Byock, MD, Director of Palliative Medicine, Dartmouth-Hitchcock Medical...
Innovative Leader in Oncology Is Committed to Tackling the Most Critical Issues in Managed Care
“I’m a Nebraskan,” said Lee N. Newcomer, MD, MHA, a leader in the oncology community who is well known for his innovative efforts to align physician payment and quality of care in ways that will best configure to the rapidly changing health-care environment. Speaking in the flat vowels and neutral...
The Power of Listening: From Candy Striper to the Front Lines of the Early AIDS Pandemic
Alexandra Levine, MD, MACP, the Chief Medical Officer of City of Hope National Medical Center, has traveled to 74 countries, seeking out adventures in some of the world’s most far-flung regions. Her illustrious oncology journey has also been an adventure, from the front lines of the AIDS pandemic...
Expert Genitourinary Oncologist's Drive Led Her from Baghdad to the United States
Born in Baghdad, Iraq, renowned prostate and bladder cancer specialist Maha H. Hussain, MD, FACP, Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center, remembers that she always wanted to become a doctor. She had strong role models in three uncles who were...
UICC President Balances Innovation and Pragmatism to Reduce the Global Burden of Cancer
Mary K. Gospodarowicz, MD, FRCPC, is determined to help reduce the worldwide burden of cancer, a problem of epic proportions. Her approach is simple: adopt what works and reject what doesn’t. Much progress in the fight against cancer can be made without waiting for the next paradigm-changing...
Pioneering Oncologist's Research on Cisplatin Revolutionized Testicular Cancer Treatment
Lawrence H. Einhorn, MD, grew up in Dayton, Ohio, in a time and place that he describes as pleasant and community-oriented. Throughout his distinguished career, Dr. Einhorn has maintained strong roots in the Midwest. “After finishing high school, I did my undergrad at Indiana University and went to ...
After a Distinguished Career, Trailblazing Swiss Oncologist Remains Devoted to Addressing the Global Cancer Challenge
Switzerland, a landlocked country with a population about that of New York City, has four geographic regions, each with its own official language. Internationally regarded lymphoma and breast cancer expert, Franco Cavalli, MD, FRCP, was born and raised in Locarno, a town in the Italian region of...
